Printer Friendly

DDT metabolite may be associated with risk for Alzheimer's.

A metabolite of the pesticide DDT banned in the United States since 1972--was associated with late-onset Alzheimer's disease in a small, case-control study.

Levels of the chemical dichlorodiphenyklichloroethylene (DDE) were nearly four times higher in the serum of Alzheimer's disease patients than in controls. That translated to almost fourfold higher odds of developing the disease, Jason R. Richardson, Ph.D., of Robert Wood Johnson Medical School, Piscataway, NJ., and his colleagues reported (JAMA Neurol. 2014 Jan. 27 [doi:10.1001/jamaneuro1.2013.6030]).

The level of the chemical also showed a strong interaction with the high-risk apolipoprotein E (apo E) epsilon-4 allele in influencing Mini-Mental State Examination (MMSE) scores, wrote Dr. Richardson and his coauthors.

"This suggests that exposure to [the chemical] may contribute to Alzheimer's disease only in a subset of cases, perhaps those with genetic polymorphisms that render them more susceptible to DDT/DDE exposure."

In 2009, the team reported a significant increase in the risk of Alzheimer's corresponding with increased levels of DDE in a small cohort of 20 Alzheimer's patients, compared with controls (Arch. Neu-rol. 2009;66:870-5 [doi:10.1001 /arch-neuro1.2009.89]).

That finding prompted this larger study, which comprised 86 Alzheimer's patients and 79 control participants from two centers, all of whom provided blood serum for testing. A subset of 11 patient samples

also provided brain tissue.

DDE, which concentrates in fat, was found in 70% of controls and 80% of cases. But the mean serum level was 3.8 times higher in cases than in controls (2.64 vs. 0.69 ng/mg cholesterol).

The authors divided the group into ter-tiles according to DDE level.

They performed a multivariate regression that controlled for age, sex, race! ethnicity and location. Compared with those with the lowest DDE level, those with the highest had significantly higher odds of Alzheimer's (odds ratio, 4.18). MMSE scores were also significantly lower in the highest tertile than in the lowest.

The presence of an apo E--epsilon-4 allele alone nearly quadrupled the odds of an Alzheimer's diagnosis (OR, 3.70), and when researchers adjusted for the risk marker, it did not change the association between DDE and Alzheimer's. However, MMSE scores were the worst in apo E--ep-silon-4 carriers who also had the highest DDE levels. Since DDE levels didn't differ by genotype, "this is a functional interaction," the investigators concluded.

Although levels of DDT and DDE have declined significantly over the past 3 decades in the United States, both DDT and DDE are still found in up to 80% of serum samples in the United States, Dr. Richardson and his team noted.

"This is likely the result of the exceptionally long half-life of DDE (approximately 8-10 years) and continuing exposure from the import of food from countries where DDT is still used or from legacy contamination of soil and waterways in the United States."

VITALS

Major finding: A metabolite of the banned pesticide DDT was associated with a fourfold increase in the risk of Alzheimer's disease.

Data source: A retrospective, case-control study comprising 86 Alzheimer's disease patients and 79 control participants

Disclosures: The study was funded by the National Institutes of Health. None of the authors reported any financial conflicts.

Caption: 'This suggests that exposure to [the chemical] may contribute to Alzheimer's disease only in a subset of cases.'

Caption: DR. RICHARDSON

BY MICHELE G. SULLIVAN

FROM JAMA NEUROLOG,
COPYRIGHT 2014 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Sullivan, Michele G.
Publication:Clinical Psychiatry News
Date:Mar 1, 2014
Words:561
Previous Article:'Target: Stroke' program gets most timely treatment.
Next Article:New fibromyalgia guidelines indicate shifting focus.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters